In last trading session, Eton Pharmaceuticals Inc. (ETON) stock price reached to $9.09 after a rally of +7.45%. The pharmaceutical firm specializes in the development and commercialization of novel therapies for uncommon diseases in children.

Eton Pharmaceuticals successfully completed a deal with Diurnal Group this month for rights to commercialize ALKINDI SPRINKLE in Canada. In the United States, Eton Pharmaceuticals is currently selling the drug as an alternate for treatment of children under the age of 17 suffering with Adrenocortical Insufficiency (AI).

CEO of Eton Pharmaceuticals, Sean Brynjelsen said that Eton has been amazed by a great deal of interest it has received from endocrinologists and caregivers in Canada since ALKINDI SPRINKLE was launched in the United States. In order to extend its relationship with DNL to include the Canadian market, Eton remained positive. The deal will allow Eton to exploit the relative success of ALKINDI SPRINKLE in the U.S. market and this will drive the company towards its ambition to become a key orphan drug manufacturer in the market.

Martin Whitaker, CEO of Diurnal Group admitted that DNL remains fascinated by Eton’s passion and vision for ALKINDI SPRINKLE. In order to eventually introduce the medicine to young children in Canada suffering from adrenal insufficiency, where there is a substantial unmet medical need, DNL has been optimistic in expanding its partnership with Eton.

Eton also filed a new drug application (NDA) for topiramate oral solution last month that was accepted by the U.S. Food and Drug Administration (FDA). The company had been assigned a date of August 6, 2021, by the FDA to comply with Prescription Drug User Fee Act (PDUFA).

Topiramate is one of three oral liquid product candidates based on neurology that has been submitted to the FDA by Eton Pharmaceuticals Inc. (ETON), and all three product candidates are expected to be approved and launched this year.